辉瑞(PFE.US)1类新药PF-07934040片在华获批临床 拟开发治疗携带KRAS突变的 ...
据辉瑞官网介绍，PF-07934040是一种泛KRAS“ON/OFF”抑制剂，具有抗野生型 (wt)KRAS和主要突变亚型的活性，对NRAS或HRAS无活性。PF-07934040显示与KRAS wt的OFF (GDP-bound)和ON ...
3.45亿美元交易背后的抗癌新药突破：解码中国药企的RAS抑制剂突围战
站在产业视角，这笔交易折射出全球抗癌药物研发的新趋势。据EvaluatePharma预测，到2030年RAS抑制剂市场规模将突破200亿美元，其中KRAS靶点占比超七成。中国创新药企通过差异化布局，正在改写全球竞争格局：在KRAS-G12C领域，安进、Mirati等国际药企已建立先发优势，而针对KRAS非经典突变及泛RAS抑制的赛道仍存巨大空白。JYP0015的临床推进，标志着我国在新一代肿瘤靶向 ...
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
pharmaphorum4 天
Jazz buys KRAS inhibitors from Redx in $880m deal
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...
pharmaphorum3 天
AstraZeneca joins KRAS push in cancer with Chinese deal
AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...
Medscape4 天
Molecular Diagnosis for Indeterminate Thyroid Nodules on Fine Needle Aspiration
The American Thyroid Association Guidelines Task Force is currently reviewing several commercially available gene expression markers to generate expert consensus guidelines for clinicians on when ...
asco.org5 天
Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
MarketWatch1 天
E-Mini S&P 500 Future Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $102.770 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.539 0.063 0.06% 10-Year U.S. Treasury Note Continuous Contract $109.266 0.094 ...